Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Mobile Health Use Predicts Self-Efficacy and Self-Management in Adolescents with Sickle Cell Disease

Anna M Hood, PhD, Cara Nwankwo, BA, Emily McTate, PhD, Naomi E Joffe, PhD, Charles T. Quinn, MD, James L Peugh, PhD, Lori E Crosby, PsyD

Blood (2020) 136 (Supplement 1): 57–58.

https://doi.org/10.1182/blood-2020-140805

Published: 2020

Journal Articles

Early Results from a Phase 1/2 Study of Aru-1801 Gene Therapy for Sickle Cell Disease (SCD): Manufacturing Process Enhancements Improve Efficacy of a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant

Michael Grimley, MD, Monika Asnani, PhD, Archana Shrestha, Sydney Felker, Carolyn Lutzko, PhD, Paritha I. Arumugam, PhD, Scott Witting, PhD, Jennifer Knight-Madden, MBBS, PhD, Omar Niss, MD, Charles T. Quinn, MD, Chris Lo, BS, Courtney R Little, BSN, Joseph W. McIntosh, MD, Punam Malik, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140963

Published: 2020

Journal Articles

Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience

Kristine Anne Karkoska, MD, Kevin E Todd, Jr., MD, Kelly Clapp, NP, Lynette Fenchel, NP, Theodosia A. Kalfa, MD PhD, Punam Malik, MD, Omar Niss, MD, Charles T. Quinn, MD, Russell E. Ware, MD PhD, Patrick T. McGann, MD MS

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-138754

Published: 2020

Journal Articles

Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia

Alina Sadaf, MD, Charles T. Quinn, MD, Jennifer B Korpik, Amanda Pfeiffer, BS, MA, Mary Reynaud, MA, MT(ASCP), Omar Niss, MD, Punam Malik, MD, Russell E. Ware, MD PhD, Theodosia A. Kalfa, MD PhD, Patrick T. McGann, MD MS

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137070

Published: 2020

Journal Articles

Leveraging Project Echo Telementoring to Improve Sickle Cell Disease Care in the Midwest: Expanding Provider Education during a Pandemic

Lisa M Shook, DHPE, Christina Bennett Farrell, MPH, Cami Mosley, MPH, Lori E Crosby, PsyD, Charles T. Quinn, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140705

Published: 2020

Journal Articles

Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-141471

Published: 2020

Journal Articles

An Immersive Virtual Reality Curriculum for Pediatric Providers on Shared Decision Making for Hydroxyurea

Lori E. Crosby, PhD, Francis J Real, MD MD, Bradley Cruse, MFA, David Davis, MFA, Melissa Klein, MD MD, Emily McTate, PhD, Anna M Hood, PhD, William Brinkman, MD MD, Rogelle Hackworth, BS, Charles T. Quinn, MD

Blood (2019) 134 (Supplement_1): 3402.

https://doi.org/10.1182/blood-2019-128661

Published: 2019

Journal Articles

Progression of Albuminuria in Sickle Cell Anemia: A Multicenter, Longitudinal Study

Omar Niss, MD, Adam Lane, PhD, Monika Asnani, PhD, Marianne McPherson Yee, MD MSc, Ashok Raj, Susan E Creary, MD, Courtney D. Fitzhugh, MD, Prasad V. Bodas, MD, Santosh L. Saraf, MD, Sharada Sarnaik, MD, Charles T. Quinn, MD, Prasad Devarajan, MD, Punam Malik, MD

Blood (2019) 134 (Supplement_1): 1004.

https://doi.org/10.1182/blood-2019-125860

Published: 2019

Journal Articles

Feasibility of Electronic Monitoring of Daily Oral Medications in Adolescents with Sickle Cell Disease

Lori E Crosby, PsyD, Katherine M Kidwell, PhD, Aimee K Hildenbrand, PhD, Charles T. Quinn, MD, Meghan E Mcgrady, PhD

Blood (2019) 134 (Supplement_1): 4701.

https://doi.org/10.1182/blood-2019-125875

Published: 2019

Journal Articles

Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve Near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis As a Benchmark for Disease-Modifying Therapy

Charles T. Quinn, MD, Omar Niss, MD, Amanda Pfeiffer, Jennifer Korpik, Holly Bonar, Mary Reynaud, Russell E. Ware, MD PhD, Patrick T. McGann, MD

Blood (2019) 134 (Supplement_1): 892.

https://doi.org/10.1182/blood-2019-130414

Published: 2019

Journal Articles

Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia

Patrick T. McGann, MD, Omar Niss, MD, Min Dong, PhD, Anu Marahatta, PhD, Tomoyuki Mizuno, PhD, Karen Kalinyak, MD, Theodosia A. Kalfa, MD PhD, Punam Malik, MD, Charles T. Quinn, MD, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD FCP

Blood (2018) 132 (Supplement 1): 507.

https://doi.org/10.1182/blood-2018-99-112909

Published: 2018

Journal Articles

Evaluation of Phenotype-Genotype Correlation in Two Common PIEZO1 Mutations p.R2456H and p.L2495_E2495dup

Mary Risinger, PhD, Vandy Black, MDMSc, Loan Hsieh, MD, Renee C. Prins, MD, Jill Menell, MD, Mohamad Badawi, MD, Cynthia Rutherford, MD, Karen L. Bride, MD PhD, Omar Niss, MD, Charles T. Quinn, MD, Katie Giger Seu, PhD, Wenying Zhang, MDPhD, Theodosia A. Kalfa, MD PhD

Blood (2018) 132 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2018-99-117299

Published: 2018

Journal Articles

Gene Therapy for Sickle Cell Anemia Using a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant Shows Promising Correction of the Disease Phenotype

Blood (2018) 132 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2018-99-119591

Published: 2018

Journal Articles

Temporal Evolution of Diffuse Myocardial Fibrosis in Sickle Cell Anemia

Charles T. Quinn, MD MS, Omar Niss, MD, Robert Fleck, MD, Tarek Alsaied, MD MSc, Punam Malik, MD, Michael D. Taylor, MD

Blood (2017) 130 (Supplement 1): 3539.

https://doi.org/10.1182/blood.V130.Suppl_1.3539.3539

Published: 2017

Journal Articles

Personalized Hydroxyurea Dosing to Reduce Time to MTD and Optimize the HbF Response: Results from the TREAT Study

Patrick T. McGann, MD MS, Omar Niss, MD, Min Dong, PhD, Anu Marahatta, PhD, Kathryn L McElhinney, BS, Thad A. Howard, MS, Tomoyuki Mizuno, PhD, Theodosia A. Kalfa, MD PhD, Karen Kalinyak, MD, Punam Malik, MD, Charles T. Quinn, MD MS, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD FCP

Blood (2017) 130 (Supplement 1): 615.

https://doi.org/10.1182/blood.V130.Suppl_1.615.615

Published: 2017

Journal Articles

Diastolic Dysfunction Is Associated with Impaired Cardiopulmonary Exercise Performance in Sickle Cell Disease

Tarek Alsaied, MD MSc, Omar Niss, MD, Adam Powell, MD, Robert Fleck, MD, Punam Malik, MD, Clifford Chin, MD, Charles T. Quinn, MD MS, Michael D Taylor

Blood (2017) 130 (Supplement 1): 3547.

https://doi.org/10.1182/blood.V130.Suppl_1.3547.3547

Published: 2017

Journal Articles

Effect of Acute Transfusion on Cerebral Oxygenation in Patients with Sickle Cell Disease

Maa-Ohui Quarmyne, MBChB, Janet Figueroa, MPH, Courtney McCracken, PhD, Charles T. Quinn, MD MS, Clark Brown, MD PhD, Clinton H. Joiner, MD PhD

Blood (2017) 130 (Supplement 1): 988.

https://doi.org/10.1182/blood.V130.Suppl_1.988.988

Published: 2017

Journal Articles

Parent and Guardian Knowledge of Hematopoietic Cell Transplantation As a Treatment Option for Sickle Cell Disease

Alicia M Stallings, BA, Navneet S. Majhail, MD MS, Amy S Nowacki, PhD, Grace I. Onimoe, MD, Rabi Hanna, MD, Jillian Wen, B.S., Charles T Quinn, MD, Lewis L. Hsu, MD PhD, Connie M. Piccone, MD

Blood (2016) 128 (22): 1307.

https://doi.org/10.1182/blood.V128.22.1307.1307

Published: 2016

Journal Articles

Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study

Patrick T. McGann, MD MS, Min Dong, PhD, Anu Marahatta, PhD, Thad A. Howard, MS, Tomoyuki Mizuno, PhD, Karen A. Kalinyak, MD, Theodosia A. Kalfa, MD PhD, Punam Malik, MD, Omar Niss, MD, Charles T Quinn, MD, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD

Blood (2016) 128 (22): 3652.

https://doi.org/10.1182/blood.V128.22.3652.3652

Published: 2016

Journal Articles

Biochemical Surrogate Markers of Hemolysis Do Not Correlate with Directly Measured Erythrocyte Survival in Sickle Cell Anemia

Charles T. Quinn, MD MS, Eric P. Smith, MD, Shahriar Arbabi, Paramjit Khera, PhD, Christopher J. Lindsell, PhD, Omar Niss, MD, Clinton H Joiner, MD PhD, Robert S. Franco, PhD, Robert M. Cohen, MD

Blood (2016) 128 (22): 2484.

https://doi.org/10.1182/blood.V128.22.2484.2484

Published: 2016

NARROW

Mobile Health Use Predicts Self-Efficacy and Self-Management in Adolescents with Sickle Cell Disease

Early Results from a Phase 1/2 Study of Aru-1801 Gene Therapy for Sickle Cell Disease (SCD): Manufacturing Process Enhancements Improve Efficacy of a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant

Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience

Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia

Leveraging Project Echo Telementoring to Improve Sickle Cell Disease Care in the Midwest: Expanding Provider Education during a Pandemic

Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease

An Immersive Virtual Reality Curriculum for Pediatric Providers on Shared Decision Making for Hydroxyurea

Progression of Albuminuria in Sickle Cell Anemia: A Multicenter, Longitudinal Study

Feasibility of Electronic Monitoring of Daily Oral Medications in Adolescents with Sickle Cell Disease

Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve Near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis As a Benchmark for Disease-Modifying Therapy

Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia

Evaluation of Phenotype-Genotype Correlation in Two Common PIEZO1 Mutations p.R2456H and p.L2495_E2495dup

Gene Therapy for Sickle Cell Anemia Using a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant Shows Promising Correction of the Disease Phenotype

Temporal Evolution of Diffuse Myocardial Fibrosis in Sickle Cell Anemia

Personalized Hydroxyurea Dosing to Reduce Time to MTD and Optimize the HbF Response: Results from the TREAT Study

Diastolic Dysfunction Is Associated with Impaired Cardiopulmonary Exercise Performance in Sickle Cell Disease

Effect of Acute Transfusion on Cerebral Oxygenation in Patients with Sickle Cell Disease

Parent and Guardian Knowledge of Hematopoietic Cell Transplantation As a Treatment Option for Sickle Cell Disease

Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study

Biochemical Surrogate Markers of Hemolysis Do Not Correlate with Directly Measured Erythrocyte Survival in Sickle Cell Anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only